Pulmatrix, Inc. (PULM)

NCM – Цена в реальном времени. Валюта: USD

1.25

0.00 (0.00%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.25

0.00 (0.00%)

После закрытия: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Pulmatrix, Inc. (PULM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pulmatrix, Inc. (PULM)

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix (PULM) Q2 Revenue Falls 100%

Видео

No Data

Пресс-релизы

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Search stocks

Pulmatrix, Inc. (PULM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pulmatrix, Inc. (PULM)

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix (PULM) Q2 Revenue Falls 100%

Видео

No Data

Пресс-релизы

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities